article thumbnail

What's Market: Alternative Dispute Resolution Provisions

JD Supra: Mergers

arbitration or mediation). In M&A purchase agreements, the parties may stipulate certain non-judicial means for dealing with claims under the agreement (e.g., These ADR provisions will govern how disputes between the parties are to be handled. Originally Published in Bloomberg Law. By: Goulston & Storrs PC

Mediation 167
article thumbnail

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Global Newswire by Notified: M&A

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Global Newswire by Notified: M&A

(Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bioâ„¢), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15

article thumbnail

Biogen Completes Acquisition of Human Immunology Biosciences

Global Newswire by Notified: M&A

(Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bioâ„¢), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs).

article thumbnail

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Global Newswire by Notified: M&A

Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have.

article thumbnail

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Global Newswire by Notified: M&A

Topline data from Phase 3 ONWARD trials for Alumis ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026

article thumbnail

Q32 Bio and Homology Medicines Announce Merger Agreement

Global Newswire by Notified: M&A

-- The combined company will operate as Q32 Bio Inc.,